TEST:

Homologous Recombination Deficiency Detection Kit

This prototype AMP-based next-generation sequencing method demonstrates a novel approach to quantification of GI, with a relatively small genomic footprint required to do so. The power of this method stems from its ability to monitor HRD at its source. By directly assigning DSBr events to their respective repair pathways, we can garner information about the DSBr pathways that are active in a tumor sample.

Different molecular assays had high accuracy for identifying deleterious BRCA1/2 alterations while exhibited a few inconsistent in identifying HRD status.